The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

J A Kemp

Work 01223 637100
Fax 01223 637111
Cambridge, London, Munich, Oxford, Paris

Andrew Bentham

Work 01223 637 100
J A Kemp

Work Department

Biotechnology and life sciences


Partner, European Patent Attorney, UK Chartered Patent Attorney


Andy joined J A Kemp from university over 20 years ago, since which time his patent practice has concentrated on global representation of UK universities and SMEs in life science fields and European Patent Office (EPO) prosecution and opposition/appeal work. Clients range from early-stage startups and spinouts through top-tier UK and foreign academic institutions to one of one of the USA's biggest biotech businesses and one of the world's largest seed companies. Chambers & Partners and The Legal 500 have both recognised Andy for his patent advice, particularly as it relates to plant sciences.

With a first class Cambridge degree in plant sciences, Andy has a particular interest in plant biotechnology, plant breeding and agri-tech and is available to advise on Plant Variety Right issues as well as patents across the agricultural sector, in which he has experience in areas including genetically modified crops, production of biopharmaceuticals in plant cell culture, breeding of crop and ornamental varieties, harvesting and crop production systems and tools for the automation of plant science research. He has a deep understanding of the complex considerations that surround patenting plants in Europe in light of the exclusion from patentability of plant varieties and essentially biological processes for the production of plants.

Andy's other current major focus relates to antibody therapeutics and technology, where he is responsible for prosecution and EPO opposition work relating to multiple antibody drug candidates that are on or nearing the market and for a large portfolio of applications and oppositions relating to transgenic animal platforms for antibody drug discovery and antibody production methodology. He has also been involved for over a decade in obtaining worldwide patent protection and now supplementary protection certificates (SPCs) around other biologics including an exceptionally successful biopharmaceutical product launched in 2011/12. This area has become increasingly contentious and Andy has therefore been involved in tens of EPO Oppositions and a number of items of UK and foreign litigation during the course of his career.

In diagnostics, Andy's work has spanned assisting in the defence of crucial early patents in the HCV area, through work on antibody-based diagnostics for one of the world's biggest diagnostics business to many patent applications for universities and recently advising a promising Cambridge-based business developing tests for prostate and bladder cancer.

Representative examples of EPO Oppositions in which Andy has been involved at EPO Board of Appeal level include T400/97 relating to early techniques for recombinant antibody production; T188/97, T748/01 and T197/02 regarding HCV diagnostics; T857/01 and T1023/02 relating to HSV vaccines and gene therapy vectors; T202/02 concerning treatment of Crohns' disease; T1219/03 and T1919/11 on taxane production in plant cell culture; T94/04 relating to ligand trap cytokine antagonists; T67/05 regarding tetanus vaccines; T1108/08 relating to plant gene silencing; T2101/09 concerning antibodies to Delta-4 proteins; and T1526/11 and T2220/14 relating to transgenic mouse platforms for antibody discovery.

Within J A Kemp, Andy leads the firm's US Business Development Group and has responsibility for the firm's relationships in Canada and Israel.

Andy joined J A Kemp in 1993 and became a partner in 2003. From 2016, he is also the head of J A Kemp's Cambridge office.


Fellow of the Chartered Institute of Patent Attorneys (CIPA), Member of the Institute of Professional Representatives before the European Patent Office (EPI)


University of Cambridge, Masters Degree in Natural Sciences (Plant Sciences)

London: TMT (technology, media and telecoms)

PATMA: Patent attorneys

Within: PATMA: Patent attorneys

J A Kemp is 'extremely meticulous in fully understanding the business context, strategies and needs' of its clients, which include NBCUniversal, University of Vienna and Pharma UK. Celia Keen is head of the chemistry and pharmaceuticals team and has extensive experience in drafting and prosecuting patents. The 'excellent' Mark Roberts is 'very knowledgeable about European patent prosecution' and 'offers prompt and appropriate advice'. Other key team members are Patrick Campbell, Kieron Grehan, Andrew Webb, and Simon Wright, who are all 'excellent lawyers'. Key mandates included Chris Milton advising Semblant on the management of its patent portfolio and Amanda Simons assisting F2G with the drafting and prosecution of its new patent applications. Other recommended individuals include Ravi Srinivasan, John Leeming, Andrew Bentham, Sarah Roques, and Graham Lewis.

[back to top]

Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to